US 12,102,560 B2
Implantable ocular drug delivery devices
Randolph E. Campbell, South San Francisco, CA (US); Kevin W. Sacherman, South San Francisco, CA (US); Bradley G. Bachelder, San Francisco, CA (US); Signe Erickson, South San Francisco, CA (US); and Jeremy Boyette, South San Francisco, CA (US)
Assigned to ForSight Vision4, Inc., South San Francisco, CA (US)
Filed by ForSight Vision4, Inc., South San Francisco, CA (US)
Filed on Feb. 14, 2023, as Appl. No. 18/169,085.
Application 18/169,085 is a continuation of application No. 16/091,493, granted, now 11,617,680, previously published as PCT/US2017/026151, filed on Apr. 5, 2017.
Claims priority of provisional application 62/318,582, filed on Apr. 5, 2016.
Prior Publication US 2023/0225903 A1, Jul. 20, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61F 9/00 (2006.01); A61K 9/00 (2006.01); A61M 31/00 (2006.01)
CPC A61F 9/0017 (2013.01) [A61K 9/0051 (2013.01); A61F 2250/0068 (2013.01)] 31 Claims
OG exemplary drawing
 
1. A drug delivery device configured to be at least partially implanted in an eye through the sclera along an axis of insertion, the device comprising:
a retention structure positioned near a proximal end region of the device comprising:
a proximal flange element configured to remain outside the sclera upon implantation of the device in the eye, the proximal flange element defining an access port into the device; and
a neck having a proximal region and a distal extension, the proximal region of the neck having a major axis dimension and a minor axis dimension,
wherein the access port of the proximal flange element extends through the proximal region of the neck defining a trans-scleral access port region of the access port and extends through the distal extension of the neck defining a sub-scleral access port region of the access port;
a penetrable element coupled to and extending within at least a portion of the access port, wherein the penetrable element has a proximal end positioned within the proximal flange element, a first portion positioned within the trans-scleral access port region, and a second portion positioned within the sub-scleral access port region, wherein a maximum distance across the proximal end and the first portion along the major axis dimension of the neck are less than a maximum distance across the second portion along the major axis dimension of the neck;
a porous drug release element positioned in fluid communication with an outlet of the device; and
a reservoir having a volume configured to contain one or more therapeutic agents and to be in fluid communication with the outlet through the porous drug release element.
 
19. A drug delivery device configured to be at least partially implanted in an eye through the sclera along an axis of insertion, the device comprising:
a retention structure positioned near a proximal end region of the device comprising:
a proximal flange element configured to remain outside the sclera upon implantation of the device in the eye, the proximal flange element defining an access port into the device; and
a neck having a proximal region and a distal extension, the proximal region of the neck having a major axis dimension and a minor axis dimension, wherein the access port of the proximal flange element extends through the proximal region of the neck defining a trans-scleral access port region of the access port and extends through the distal extension of the neck defining a sub-scleral access port region of the access port;
a penetrable element coupled to and extending within at least a portion of the access port, wherein the penetrable element has a proximal end positioned within the proximal flange element, a first portion positioned within the trans-scleral access port region, and a second portion positioned within the sub-scleral access port region, wherein a maximum distance across the proximal end and the first portion along the major axis dimension of the neck are less than a maximum distance across the second portion along the major axis dimension of the neck;
a porous drug release element positioned in fluid communication with an outlet of the device; and
a reservoir having a volume configured to contain one or more therapeutic agents and to be in fluid communication with the outlet through the porous drug release element, wherein the proximal region of the neck is flared and the access port extending through the proximal region of the neck into the reservoir is tapered.